IDH wild-type

These findings indicated that DMC functions as an effective chemosensitizer, elevating TMZ efficacy. Combining DMC with DNA repair inhibitors may represent a promising therapeutic strategy to overcome resistance and improve IDH-wildtype grade diffuse glioma treatment outcomes.

P1, N=52, Recruiting, EMD Serono Research & Development Institute, Inc. | Trial completion date: Mar 2028 --> Apr 2027 | Trial primary completion date: Mar 2027 --> Oct 2026

These molecules were further used for the establishment of piRNA signature predicting survival of GBM patients. Our results, not only, confirm the important role of piR-9491 in GSCs, but also indicate potentially significant role of piRNAs in the biology of GBM.

P1, N=12, Recruiting, University of Virginia

P1, N=60, Active, not recruiting, Northwestern University | Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2027 --> Jan 2026

P2, N=108, Recruiting, Tata Memorial Centre

Interestingly, C269 autopalmitoylation occurs within a hydrophobic pocket, targeted by a clinical IDH1-mutant inhibitor (LY3410738). Our study reveals that autopalmitoylation, conferred by the IDH1R132H mutation, links fatty acid metabolism to the regulation of IDH1 mutant activity and represents a druggable vulnerability in IDH1-mutant cancers.

Original method based on marker gene expression ratios does not replace standard diagnostic protocols, but may be an additional tool for optimized diagnostic process. This approach will be valuable to minimize errors and personalize therapeutic strategies. The last one is critical for prognosis.

The IDH1-wt group showed higher amplitude of MMN evoked by novel stimulus at Fz and Cz and longer latency of the P300 component evoked by a deviant stimulus at Fz. The combination of AERP parameters yielded a more effective means to predict IDH1 mutation status in patients with insular glioma, which may provide guidance for the surgical intervention of this disease.

Cox proportional-hazards analysis showed worse survival with higher CD8+ and CD45+ infiltration in primary GBM, and higher CD45+ and CD68+ infiltration in recurrent GBM. In conclusion, we propose a feasible, cost-efficient, and robust method to assess immune infiltration on FFPE material, enabling standardized comparison of inflammation, with applications for ongoing clinical trials.

Here, we evaluated the survival outcomes between temozolomide (TMZ)-only and TMZ + BEV treatments stratified based on the cyclooxygenase-2 (COX-2) expression, a rate-limiting enzyme involved in the cancer development. In contrast, these benefits were not found in patients with low COX-2 expression (PFS: 12 vs. 15 months, p = 0.875; OS: 24 vs. 26 months, p = 0.775). Altogether, this study suggests that patients with high, but not low, COX-2 expression demonstrate survival benefits from the addition of BEV in ndGBM.

Despite the exploratory nature of the analysis on a small population, the study underscores the biological and transcriptional heterogeneity of LGGs and highlights the limitations of tumor-only sequencing approaches. Broader genomic profiling and matched normal controls are warranted to refine the interpretation of rare or non-canonical variants.